Last reviewed · How we verify
Human papillomavirus genotyping
At a glance
| Generic name | Human papillomavirus genotyping |
|---|---|
| Sponsor | CHU de Reims |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Detecting HPV DNA in Anal and Cervical Cancers
- HPV Genotype Attribution and Disease Burden of Anal Cancer in China
- Primary HPV-based Cervical Cancer Screening Algorithms in Botswana (NA)
- Cervical Cancer Screening of Postmenopausal Women in Low- and Middle-income Countries Using HPV Self-sampling and Triage by Genotyping and Cytology
- A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
- Optimization of Cervical Cancer Screening Among Women Living With HIV in Latin American Countries (NA)
- A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer (EARLY_PHASE1)
- Clinical Trial for Registration of HPV Nucleic Acid Genotyping Assay Kit (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Human papillomavirus genotyping CI brief — competitive landscape report
- Human papillomavirus genotyping updates RSS · CI watch RSS
- CHU de Reims portfolio CI